Advaxis — Investor Presentation (September 2013)
27 slides from Advaxis's investor presentation, Sep 30, 2013
Slide 1: September 2013 Corporate Presentation
2013 Advaxis, Inc. | OTCQB:ADXS Ticker: ADXS September 2013 Corporate Presentation Empowering the immune system from within™
Slide 2: Forward Looking Statements
2013 Advaxis, Inc. | OTCQB:ADXS Forward Looking Statements This presentation contains forward - looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectat
Slide 3: Experienced Management Team & Board of Directors
2013 Advaxis, Inc. | OTCQB:ADXS Experienced Management Team & Board of Directors Management Team Daniel J. O ’ Connor, Esq. President and Chief Executive Officer ▪ 15 years of executive, legal, regulatory, compliance, manufacturing and quality experience in the biopharmaceutical industry ▪ Former Se
Slide 4: Investment Highlights
2013 Advaxis, Inc. | OTCQB:ADXS Investment Highlights Immunotherapy company with cutting - edge, proprietary platform technology in the hottest area of oncology 4 Lead drug candidate, ADXS - HPV (ADXS11 - 001), targets HPV - associated cancers with multiple registration opportunities Comprehensive,
Slide 5: Four Essentials of Cancer Immunotherapy
2013 Advaxis, Inc. | OTCQB:ADXS Four Essentials of Cancer Immunotherapy 5 Access to Antigen Presenting Cells (APCs) to direct and target the immune response Advaxis immunotherapies preferentially infect the APCs and escape into the cytoplasm to secrete antigens for the targeted tumor (Dendreon) ▪ Ot
Slide 6: Advaxis Approach: Elements in Action
2013 Advaxis, Inc. | OTCQB:ADXS Advaxis Approach: 4 Elements in 1 6 Access APC, Secrete LLO - TAA, MHC1 CD8 T cell Expansion, Pass Checkpoints Chemokines, Tumor Infiltration Dec. Treg, MDSCs, Tumor Cell Lysis 1 2 3 4
Slide 7: Proprietary Technology Platform Fuels Robust Clinical Pipeline
2013 Advaxis, Inc. | OTCQB:ADXS Product Candidate Pre Phase 1 Phase 2 Phase 3 ADXS - HPV 1 ADXS - HPV 2 ADXS - HPV 3 ADXS - PSA ADXS - cHER2 Veterinary Program ADXS - cHER2 Canine Osteosarcoma Cervical Cancer, India Head & Neck Cancer Anal Cancer Prostate Cancer Breast Cancer Proprietary Technology
Slide 8: Advaxis Platform Yields Numerous Product Candidates
2013 Advaxis, Inc. | OTCQB:ADXS Advaxis Platform Yields Numerous Product Candidates ▪ Lm can secrete extracellular, intracellular or transmembrane regions ▪ Lm can express proteins with different functions such as enzymes, receptors, transcription factors, etc. ▪ Chimeric molecules can be created by
Slide 9: Multiple Phase 1/2 Clinical Trials
2013 Advaxis, Inc. | OTCQB:ADXS Multiple Phase 1/2 Clinical Trials ▪ Safety: predominately cytokine - release syndrome - Grade 1/2 transient, non - cumulative that respond to symptomatic treatment or self resolve (<3.0% related SAEs) ▪ Efficacy: improved survival, complete responses, partial respons
Slide 10: A Targeted Therapy with Multiple Registration Opportunities
2013 Advaxis, Inc. | OTCQB:ADXS ADXS - HPV – A Targeted Therapy with Multiple Registration Opportunities Immunotherapy targeting HPV - associated cancers HPV - associated cancers include: invasive cervical, HPV+ head & neck, anal, penile, vulvar, and vaginal ▪ Single agent activity observed in recur
Slide 11: Growth in HPV-associated Cancers Increases Global Opportunity
2013 Advaxis, Inc. | OTCQB:ADXS Growth in HPV - associated Cancers Increases Global Opportunity for ADXS - HPV ▪ HPV has a causative role in 5% of cancers worldwide ▪ 80% of sexually active Americans will have contracted at least one strain of HPV by age 50 per the CDC ▪ Current vaccines prevent inf
Slide 12: Opportunistic Business Development Strategy
2013 Advaxis, Inc. | OTCQB:ADXS Confidential discussions with multiple partners for the licensing of immunotherapies Licensing of ADXS - HPV Opportunistic Business Development Strategy Initially Focusing on High Prevalence Regions 12 Asia ▪ Signed MoU for commercialization in Asia ▪ Clinical strateg
Slide 13: Phase 2 Study Overview
2013 Advaxis, Inc. | OTCQB:ADXS ADXS - HPV Phase 2 Study Overview ▪ Multi - center Phase 2 trial conducted in India ▪ Recurrent cervical cancer patients ▪ Failed previous treatments, ECOG 0 - 2, majority with aggressive disease ▪ Single agent activity with a single cycle of ADXS - HPV (3 doses) ▪ Ap
Slide 14: Phase 2 Cervical Cancer Study Design
2013 Advaxis, Inc. | OTCQB:ADXS 3m 6m 9m 12m 18m Phase 2 Cervical Cancer ADXS - HPV +/ - Cisplatin Study Design 14 Recurrent/Refractory Cervical (N = 110) Arm A N = 55 ADXS Only Arm B N = 55 ADXS+Cisplatin Treatment Follow - up Phase Scans ADXS ADXS ADXS ADXS ADXS ADXS 3m 6m 9m 12m 18m R ADXS C C C
Slide 15: Phase 2 Best Response Data
2013 Advaxis, Inc. | OTCQB:ADXS -100% -75% -50% -25% 0% 25% 50% 75% 100% 125% 150% 121006 100008 128001 124011 116007 111005 104006 109009 105007 111001 121001 107006 101007 107003 107007 110010 107005 113001 110016 107008 109004 116003 115004 112005 128002 110008 110012 113010 104001 100019 104003
Slide 16: Patient 002: Major Tumors Eliminated
2013 Advaxis, Inc. | OTCQB:ADXS Patient 110 - 002: Major Tumors Eliminated 16 Resolution of lung metastasis on CT Resolution of liver metastasis on CT Resolution of para - aortic lymph node metastasis on CT* Patient # First Line Tx Stage Tx Arm Tumor Burden (mm) Tumor Decrease Baseline 3 mo. 6 mo. 9
Slide 17: Landmark Survival
2013 Advaxis, Inc. | OTCQB:ADXS *Patients continue to be followed for survival 17 ▪ Final 12 month survival of 36% with a (current) 18 month survival of 22% we believe to be notable in this disease setting ▪ Overall survival observed with ADXS11 - 001 is consistent with an active agent in recurrent
Slide 18: Prognostic Factors for Overall Survival in Cervical Cancer
2013 Advaxis, Inc. | OTCQB:ADXS Trial Regimen N PS (%) 1 st line Prior Chem Prior RT %SAE Reported % CR Med. Surv. Resp. Durat. 12 Mo. Surv. 18 Mo. Surv. 24 Mo. Surv. Moore 2004 Cisplatin 134 0 - 2 (48/44/8) 6% 24% 91% 134% 0 deaths 8% 9M 4.5M ~36% ~12% ~5% Cis+ Taxol 130 (45/42/13) 177% 0 deaths 15
Slide 19: Registration Opportunity in Cervical Cancer
2013 Advaxis, Inc. | OTCQB:ADXS Next steps towards registration in this highly aggressive malignancy ▪ Report final results from Phase 2 study in India at SITC annual meeting in November ▪ Orphan designation pending ▪ Conduct Phase 1/2 study with high dose, immunology endpoints and repeat cycles ▪ C
Slide 20: Registration Opportunity in Head & Neck Cancer
2013 Advaxis, Inc. | OTCQB:ADXS Registration Opportunity for ADXS - HPV in Head & Neck Cancer 20 Rationale for registering ADXS - HPV in head and neck cancer ▪ HPV+ head & neck cancer is increasing at an epidemic rate due to changing sexual practices ▪ 25%+ of head % neck cancer caused by HPV ▪ Curr
Slide 21: Registration Opportunity in Anal Cancer
2013 Advaxis, Inc. | OTCQB:ADXS Registration Opportunity for ADXS - HPV in Anal Cancer Orphan designation granted 21 Rationale for registering ADXS - HPV in anal cancer ▪ 80 - 100% caused by HPV ▪ Current therapies are toxic and have long term side effects ▪ No therapy for recurrent disease ▪ Exclus
Slide 22: ADXS-PSA for the Treatment of Prostate Cancer
2013 Advaxis, Inc. | OTCQB:ADXS ADXS - PSA for the Treatment of Prostate Cancer 22 ADXS - PSA ▪ Immunotherapy targeting cells expressing PSA ▪ Conducted a pre - IND meeting with the FDA to discuss the CMC, pharmacology, toxicology, and clinical plans for ADXS - PSA ▪ Exclusive world - wide rights Ne
Slide 23: ADXS-cHER2 for HER2 Overexpressing Cancers
2013 Advaxis, Inc. | OTCQB:ADXS Immunotherapy targeting cancers overexpressing HER2, including breast cancer in addition to others ADXS - cHER2 For the Treatment of HER2 Overexpressing Cancers Veterinary Program ▪ We believe canine osteosarcoma (CO) provides excellent animal model of naturally occur
Slide 24: Key Milestones Expected to Continue to Build Momentum
2013 Advaxis, Inc. | OTCQB:ADXS Key Milestones Expected to Continue to Build Momentum 24 Reporting of final Phase 2 data from India cervical cancer trial at SITC Filing IND application with the FDA for ADXS - PSA for the treatment of prostate cancer Initiation of dialogue with the FDA to establish c
Slide 25: Investment Highlights
2013 Advaxis, Inc. | OTCQB:ADXS Investment Highlights Immunotherapy company with cutting - edge, proprietary platform technology in the hottest area of oncology 25 Lead drug candidate, ADXS - HPV (ADXS11 - 001), targets HPV - associated cancers with multiple registration opportunities Comprehensive,
Slide 26: Advaxis, Inc.
2013 Advaxis, Inc. | OTCQB:ADXS 26 Advaxis , Inc. 305 College Road East Princeton, NJ 08540 T: 609.452.9813 ir@advaxis.com www.advaxis.com
Slide 27: Strong Patent Portfolio
2013 Advaxis, Inc. | OTCQB:ADXS Strong Patent Portfolio 41 patents issued ▪ Composition of matter, methods and uses covering: ▪ Live Lm ▪ Four (4) different Listeria species for human use ▪ LLO - antigen & ActA - antigen fusion proteins ▪ Delivered by Lm or stand alone ▪ Two (2) different families o